参考文献 References
[1] Cho NH，Shaw JE，Karuranga S，et al. IDF Diabetes Atlas：Global estimates of diabetes prevalence for 2017 and projections for 2045 [J]. Diabetes Res Clin Pract，2018，138：271- 281.
[2] 霍启东,李德冠.恩格列净在2型糖尿病治疗中的研究进展[J].中国医药导报,2023,20(16):37-40+49.
[3] Chen J, Williams S, Ho S, et al.Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members[J].Diabetes, 2010, 1 (2) :57-92.
[4] Tahrani AA, Barnett AH, Bailey CJ.et al. SGLT inhibitors in management of diabetes[J].Lancet Diabetes Endocrinol, 2013, 1 (2) :140-151.
[5] Wright EM. Renal Na+-glucose cotransporters[J].Am J Physiol Renal Physiol, 2001, 280 (1) :F10-F18.
[6] 倪倩,封宇飞,裴艺芳等.达格列净的药理及临床研究概述[J].中国药师,2014,17(11):1947-1949.
[7] US Food and Drug Administration. FDA labelling information FARXIGA. FDAwebsite[EB/OL], 2014-01-08 /2014 -01-18.
[8] MerovciA, Solis-HerreraC, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production[J]. JClin Invest, 2014, 124 (2) :509-514.
[9] 郭思言,孙亚东.达格列净临床应用与血压相关性研究进展[J].吉林医学,2023,44(04):1069-1072.
[10] Dhillon S. Dapagliflozin: A Review in Type 2 Diabetes. Drugs. 2019 Jul;79(10):1135-1146.
[11] 杨哲普，毕会民.SGLT-I和SGLT-2在肾内、肾外器官中的作用研究进展[J].疑难病杂志，2016,15(11):1206-1209.
[12] 孔小敏,刘彦,谭波宇等.SGLT-2抑制剂联合二甲双胍、DPP-4抑制剂治疗2型糖尿病疗效和安全性的Meta分析[J].中国新药与临床杂志,2017,36(12):723-729.
[13] 马静.达格列净治疗2型糖尿病患者的应用进展[J].现代诊断与治疗,2021,32(16):2544-2545+2589.
[14] Liu JJ, Lee T,DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30%-50% of renal glucose reabsorption in humans[J]?Diabetes,2012,61(9):2199-2204.
[15] MerovciA, Solis-HerreraC, Daniele G,et al. Dapagliflozin improves musele insulin sensitivity but enhances endogenous glucose production[J].J Clin Invest,2014,124(2):509-514.
[16] Yang W,Ji L,Zhou Z,et al.Efficacy and safety of dapagliflozin in Asian patients:a pooled analysis[J].J Diabetes,2017, 9(8):787-799.
[17] Bailey CJ, Gross JL, Pieters A,et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control withmetformin:arandomised,doubleblind,placebo-controlledtrial[J].Lancet,2010,375(9733):2223-2233.
[18] 杨隽,盛威,蔡贞玉.HSP70,NO在妊娠期高血压疾病孕妇血清中的表达及其意义[J].医学临床研究,2019,36(12): 2426-2428.
[19] 海长娥,王丽萍.HPA、MMP-9、AGEs、RAGE及HSP70在妊娠期高血压患者血清及胎盘中的表达分析[J].河北医药,2019,41(5):113-116.
[20] McMurray JJV, Solomon SD, Inzucchi SE, act; DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.
[21] Scheen AJ, Paquot N. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: a review of the clinical evidence. Diabetes Metab. 2014;40(6 Suppl 1):S4–11.
[22] 马子君.SGLT2抑制剂对D-半乳糖致衰老小鼠保护作用及其机制研究[D].湖北医药学院,2023.
[23] Hu J, Xu J, Tan X, Li D, Yao D, Xu B, Lei Y. Dapagliflozin protects against dilated cardiomyopathy progression by targeting NLRP3 inflammasome activation. Naunyn Schmiedebergs Arch Pharmacol.2023Jul;396(7):1461-1470.
[24] 谢丽芬,欧阳山丹,戴小霞.通脉降糖胶囊联合达格列净片治疗2型糖尿病的疗效及对患者胰岛功能的影响[J].临床合理用药,2024,17(09):16-19.
[25] McMurray JJV, Wheeler DC, Stef nsson BV, et al.Effect of da-pagliflozin on clinical outcomes in patients with chronic kidneydisease, with and without cardiovascular disease[J].Circula-tion,2021,143(5):438-448.DOI:10.1161/CIRCULATIONAHA.120.051675.
[26] Zaina A, Grober Y,Abid A, et al.S odium glucose cotransport-er 2 inhibitors treatment in acromegalic patients with diabe-tes-A case series and literature review[J].Endocrine, 2021, 73(1):65-70.
[27] Wiviott SD, Raz I, Bonaca MP, et al. Dagliflozin and cardiovascular outcomes in type 2 diabetes.N Engl J Med. 2018;380(4):347-357.
[28] Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Eng J Med,2015,373(22):2117-2128.
[29] Jabbour S,Seufert J,Scheen A,et al.Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase Ⅱb/Ⅲ clinical trials[J].Diabetes Obes Metab,2018,20(3):620-628.
[30] 郑秋美,周才福.达格列净联合沙格列汀治疗2型糖尿病的血糖指标及不良反应[J].吉林医学,2023,44(11):3120-3122.
[31] 陈小翠,周望,王艺霖,等.胰岛素强化治疗联合达格列净治疗老年初诊2型糖尿病效果及安全性[J].中国老年学杂志,2024,44(08):1800-1803.
[32] AstraZeneca. forxiga (dagliflozin): summary of product characteristics. 2019.14.Kohan DE, Fioretto P, Tang W, et al. Long-term study of patients with type 2 diabetes and moderate renal insufficiency shows that dagliflozin reduces weight and blood pressure but does not improve glycaemic control. Kidney Int 2014;85(4):962-71.
[33] Danne T, Garg S, Peters AL, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter protein (SGLT) inhibitors. Diabetes Care. 2019;42(6):1147-54.